1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Australia’s GBMA Aims To Educate With ‘Biosimilar Week’

 
• By Dave Wallace

Australia’s GBMA industry association will seek to promote biosimilars through a dedicated ‘Biosimilar Week’ in late April and early May this year, running as part of a three-year education program being pursued by the association and industry stakeholders.

Australia_Crowd
The GBMA Is Hoping To Reach A Larger Crowd With Its Education Efforts • Source: Shutterstock

A week-long campaign to “focus on the role of biosimilars in supporting a sustainable healthcare system” has been launched by Australia’s Generic and Biosimilar Medicines Association (GBMA), to run from 29 April to 3 May this year.

Developed “collaboratively, by representatives across medical specialities, government health experts and the medicines industry”, Biosimilar Week will begin with an official announcement from Australian health minister Greg Hunt, “highlighting the critical role that

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”